Calliditas Therapeutics AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CALT research report →
About the company
Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets Nefecon, an orally administered formulation of budesonide, which functions as an immunosuppressive agent designed to address immunoglobulin A nephropathy, an autoimmune kidney disease.
- CEO
- Renee Aguiar-Lucander
- IPO
- 2020
- Employees
- 222
- HQ
- Stockholm, SE
Price Chart
- Market Cap
- $2.15B
- P/E
- -23.95
- P/S
- 9.31
- P/B
- 33.34
- EV/EBITDA
- -30.57
- Div Yield
- 0.00%
- Gross Margin
- 93.62%
- Op Margin
- -31.85%
- Net Margin
- -38.63%
- ROE
- -84.68%
- ROIC
- -25.31%
- Revenue
- $1.21B · 50.32%
- Net Income
- $-466,185,000 · -13.08%
- EPS
- $-17.38 · -11.70%
- Op Income
- $-384,397,000
- FCF YoY
- -42.56%
- 52W High
- $43.00
- 52W Low
- $15.25
- 50D MA
- $39.65
- 200D MA
- $29.60
- Beta
- 1.46
- Avg Volume
- 7.73K
Get TickerSpark's AI analysis on CALT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CALT coverage
Recent articles, reports, and earnings notes.
No research on CALT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CALT report →Similar companies
Peers in the same neighborhood.